| Date |
Event |
Presentation |
Speakers |
|
September 9, 2013
|
6th CNS Partnering and Deal Making Conference
|
Panel Discussion: Current and Future Trends in CNS Development
|
Mary Martinson
|
|
April 6, 2013
|
AACR Annual Meetings
|
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 2: Targeting Epigenetics: An Epicenter of Oncology Drug Discovery? Chairperson: Ho Man Chan, Novartis Institutes for BioMedical Research, Cambridge, MA
|
Dashyant Dhanak
|
|
|
|
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Oncology Drug Discovery and Development: Combination Therapies Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC
|
Tona M Gilmer, Axel Hoos
|
|
September 3, 2012
|
Ourense Conference on Imaging Mass Spectrometry
|
Observing Directly the Distribution of an Inhaled Domain Antibody in Healthy and Infected Mice by MALDI MS Imaging
|
Peter S. Marshall
|
|
January 5, 2009
|
High Content Analysis
|
Primary HCS for Immunomodulation
|
Carmel B Nanthakumar
|
|
February 19, 2008
|
Screening Europe
|
Track B The Industrialisation of 1536 Well Format High Throughput Screening for Modulators of G Protein-Coupled Receptors
|
Stuart Baddeley
|
|
September 24, 2007
|
High-Content Analysis Europe: High content Cellular Assays for compound screening and Pahtway Analysis (Sep 24-26)
|
HCA for Mechanism-of-Action Studies: Use of the BD Pathway in CNS Drug Discovery to Determine Mechanisms of Compound Action in Primary Neuronal Cultures (16:00-16:30)
|
Claire Scott
|
|
|
|
HCA for Mechanism-of-Action Studies (16:00-18:00)
|
Claire Scott
|
How We Rank